


PRODUCT INFORMATION



LXR-623

Item No. 21117

CAS Registry No.: 875787-07-8
Formal Name: 2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole
Synonym: WAY-252623
MF: C₂₁H₁₂ClF₅N₂
FW: 422.8
Purity: ≥98%
UV/Vis.: λ_{max}: 209, 318 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LXR-623 is supplied as a crystalline solid. A stock solution may be made by dissolving the LXR-623 in the solvent of choice, which should be purged with an inert gas. LXR-623 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LXR-623 in these solvents is approximately 30 mg/ml.

LXR-623 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LXR-623 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. LXR-623 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LXR-623 is a liver X receptor (LXR) modulator that acts as a partial agonist at LXRA and a full agonist at LXRβ (IC₅₀s = 179 and 24 nM, respectively).^{1,2} It is orally bioavailable and readily passes the blood-brain barrier.¹⁻³ LXR-623 is anti-atherogenic in animal models of atherosclerosis, showing synergistic effects when combined with simvastatin (Item Nos. 10010344 | 10010345).^{1,2,4}

References

- DiBlasio-Smith, E., Arai, M., Quinet, E.M., *et al.* Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. *J. Transl. Med.* **6**, 59 (2008).
- Quinet, E.M., Basso, M.D., Halpern, A.R., *et al.* LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. *J. Lipid. Res.* **50(12)**, 2358-2370 (2009).
- Villa, G.R., Hulce, J.J., Zanca, C., *et al.* An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. *Cancer Cell.* **30(5)**, 683-693 (2016).
- Giannarelli, C., Cimmino, G., Connolly, T.M., *et al.* Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: An magnetic resonance imaging study in a model of advanced atherosclerosis. *Eur. Heart J.* **33(2)**, 264-273 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM